The University of Tennessee: Licensing Deal Finalized for Cancer-Targeting Antibodies

A little over six months ago, IN-PART matched a global life science company to a novel cancer-targeting antibody developed by scientists at the University of Tennessee. After a series of discussions and negotiations, a licensing agreement was recently finalized.

Stefan Schweizer, Licensing Associate at the University of Tennessee, shared with us the story of how the collaboration developed:

“For a monoclonal antibody related to cancer, IN-PART connected us with a major supplier of biological products for the research community. The initial introduction led to licensing discussions, and earlier this year we signed a non-exclusive licensing agreement that makes the antibody available as a non-clinical research tool.

“As with the Huntington’s Disease technology that we are now co-developing with a global biopharma company, I think we wouldn’t have reached the European corporate partner without IN-PART building the bridge first.”

Academics at The University of Tennessee Health Science Center targeted a newly identified transmembrane mucin (MUC13) that is highly overexpressed in pancreatic, colorectal, stomach and ovarian cancers.

The researchers showed that MUC13 can be used as a biomarker for early detection of aggressive cancers, and developed a novel set of highly specific mouse monoclonal and humanized recombinant antibodies that target MUC13, which can be delivered as antibody-drug conjugates or attached to drug-containing nanoparticles for targeted drug delivery.

Read the case study of the collaboration between The University of Tennessee and a global biopharmaceutical company who are working to co-develop a novel gene therapy for Huntington’s Disease.

Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2018


Header image background: Patho / Wikimedia Commons (CC SA 3.0)

Working in a company?

Gain a competitive advantage by identifying cutting-edge innovation and expertise from universities and institutes worldwide.

Get started

Are you an academic?

Advance research, generate impact and secure funding by partnering with industry teams around the world.

Get started

Part of a university?

Engage with industry teams from all sectors looking for a wide range of opportunities from early-stage to late-stage research, technologies, spin-outs and expertise for consultancy.

Request a demo